Inflammation and Cardiovascular Disease: The Future
Despite considerable advances in reducing the global burden of atherosclerotic cardiovascular disease by targeting conventional risk factors, significant residual risk remains, with low-grade inflammation being one of the strongest risk modifiers. Inflammatory processes within the arterial wall or s...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2021-05-01
|
| Series: | European Cardiology Review |
| Online Access: | https://www.ecrjournal.com/articleindex/ecr.2020.50 |
| _version_ | 1797200073648504832 |
|---|---|
| author | Natalie Arnold Katharina Lechner Christoph Waldeyer Michael D Shapiro Wolfgang Koenig |
| author_facet | Natalie Arnold Katharina Lechner Christoph Waldeyer Michael D Shapiro Wolfgang Koenig |
| author_sort | Natalie Arnold |
| collection | DOAJ |
| description | Despite considerable advances in reducing the global burden of atherosclerotic cardiovascular disease by targeting conventional risk factors, significant residual risk remains, with low-grade inflammation being one of the strongest risk modifiers. Inflammatory processes within the arterial wall or systemic circulation, which are driven in a large part by modified lipoproteins but subsequently trigger a hypercoagulable state, are a hallmark of atherosclerotic cardiovascular disease and, in particular, its clinical complications. Extending conventional guideline-based clinical risk stratification algorithms by adding biomarkers of inflammation may refine phenotypic screening, improve risk stratification and guide treatment eligibility in cardiovascular disease prevention. The integration of interventions aimed at lowering the inflammatory burden, alone or in combination with aggressive lipid-modifying or even antithrombotic agents, for those at high cardiovascular risk may hold the potential to reduce the still substantial burden of cardiometabolic disease. This review provides perspectives on future clinical research in atherosclerosis addressing the tight interplay between inflammation, lipid metabolism and thrombosis, and its translation into clinical practice. |
| first_indexed | 2024-03-07T17:41:20Z |
| format | Article |
| id | doaj.art-c298196d799e49f5b196ebfb168e1c33 |
| institution | Directory Open Access Journal |
| issn | 1758-3756 1758-3764 |
| language | English |
| last_indexed | 2024-04-24T07:25:51Z |
| publishDate | 2021-05-01 |
| publisher | Radcliffe Medical Media |
| record_format | Article |
| series | European Cardiology Review |
| spelling | doaj.art-c298196d799e49f5b196ebfb168e1c332024-04-20T16:02:13ZengRadcliffe Medical MediaEuropean Cardiology Review1758-37561758-37642021-05-011610.15420/ecr.2020.50Inflammation and Cardiovascular Disease: The FutureNatalie Arnold0Katharina Lechner1Christoph Waldeyer2Michael D ShapiroWolfgang Koenig3Department of Cardiology, University Heart and Vascular Center Hamburg; Hamburg, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Luebeck, Hamburg, GermanyDeutsches Herzzentrum München, Technische Universität München, Munich, Germany; German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, GermanyDepartment of Cardiology, University Heart and Vascular Center Hamburg; Hamburg, Germany; German Center for Cardiovascular Research (DZHK), Partner Site Hamburg/Kiel/Luebeck, Hamburg, GermanyDeutsches Herzzentrum München, Technische Universität München, Munich, Germany; German Centre for Cardiovascular Research (DZHK), Partner Site Munich Heart Alliance, Munich, Germany; Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, GermanyDespite considerable advances in reducing the global burden of atherosclerotic cardiovascular disease by targeting conventional risk factors, significant residual risk remains, with low-grade inflammation being one of the strongest risk modifiers. Inflammatory processes within the arterial wall or systemic circulation, which are driven in a large part by modified lipoproteins but subsequently trigger a hypercoagulable state, are a hallmark of atherosclerotic cardiovascular disease and, in particular, its clinical complications. Extending conventional guideline-based clinical risk stratification algorithms by adding biomarkers of inflammation may refine phenotypic screening, improve risk stratification and guide treatment eligibility in cardiovascular disease prevention. The integration of interventions aimed at lowering the inflammatory burden, alone or in combination with aggressive lipid-modifying or even antithrombotic agents, for those at high cardiovascular risk may hold the potential to reduce the still substantial burden of cardiometabolic disease. This review provides perspectives on future clinical research in atherosclerosis addressing the tight interplay between inflammation, lipid metabolism and thrombosis, and its translation into clinical practice.https://www.ecrjournal.com/articleindex/ecr.2020.50 |
| spellingShingle | Natalie Arnold Katharina Lechner Christoph Waldeyer Michael D Shapiro Wolfgang Koenig Inflammation and Cardiovascular Disease: The Future European Cardiology Review |
| title | Inflammation and Cardiovascular Disease: The Future |
| title_full | Inflammation and Cardiovascular Disease: The Future |
| title_fullStr | Inflammation and Cardiovascular Disease: The Future |
| title_full_unstemmed | Inflammation and Cardiovascular Disease: The Future |
| title_short | Inflammation and Cardiovascular Disease: The Future |
| title_sort | inflammation and cardiovascular disease the future |
| url | https://www.ecrjournal.com/articleindex/ecr.2020.50 |
| work_keys_str_mv | AT nataliearnold inflammationandcardiovasculardiseasethefuture AT katharinalechner inflammationandcardiovasculardiseasethefuture AT christophwaldeyer inflammationandcardiovasculardiseasethefuture AT michaeldshapiro inflammationandcardiovasculardiseasethefuture AT wolfgangkoenig inflammationandcardiovasculardiseasethefuture |